866-997-4948 (US-Canada Toll Free)

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

Published By :

GBI Research

Published Date : 2013-04-15

Category :

Pharmaceutical

No. of Pages : N/A

Product Synopsis

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.  The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary... Read More

Table Of Content

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to 2018 – Executive Summary

3 ADHD Therapeutics Market to 2018 – Introduction
3.1 Etiology and Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
3.2.1 Child/Adult Subpopulations
3.2.2 Male/Female
3.3 Diagnosis
3.3.1 DSM-IV Criteria for ADHD
3.3.1.1 DSM-V Revision
3.3.2 ICD-10 Criteria for Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues with Diagnosis
3.3.5 Co-Morbid Disorders
3.4 Treatment and Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers and Barriers for ADHD Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence of ADHD
3.5.1.2 Need for Effective Non-Stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level of Co-Morbidity
3.6 Report Guidance

4 ADHD Therapeutics: Market Characterization by Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost of Therapy – Average of All Major Markets
4.2 The US
4.2.1 Market Size – The US
4.2.2 Market Forecast - The US
4.2.3 Annual Cost of Therapy – The US
4.3 Top 5 Countries of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
4.3.12 Annual Cost of Therapy – Spain
4.3.13 Market Size – The UK
4.3.14 Market Forecast – The UK
4.3.15 Average Annual Cost of Therapy – The UK
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost of Therapy – Japan

5 ADHD Therapeutics Market to 2018 – Competitive Landscape
5.1 Overview of Major Marketed Products in the ADHD market
5.1.1 Adderall XR (mixed amphetamine salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate transdermal patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin XR (dexmethylphenidate hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
5.1.8.3 Safety
5.1.9 Generic products

6 ADHDTherapeutics Market to 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
6.3 Trends in the ADHD Therapeutic Pipeline

7 ADHD Therapeutics Market to 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals by Deal Type
7.1.2 Deals by Year
7.1.3 Deals by Geography
7.1.4 Deals by Value
7.2 M&A Landscape
7.2.1 M&A Deals by Deal Type
7.2.2 M&A Deals by Year
7.2.3 M&A Deals by Geography
7.2.4 M&A Deals by Deal Value
7.2.5 Sanofi-Aventis Merger, 2004
7.3 R&D Licensing Agreements
7.3.1 Deals by Year
7.3.2 Deals by Geography
7.3.3 Deals by Deals Value
7.3.4 Targacept and AstraZeneca Agreement, 2009
7.4 Co-Development Agreements
7.4.1 Deals by Year
7.4.2 Deals by Geography
7.4.3 Deals by Deal Value
7.4.4 Shire and New River Co-Development Deal, 2005

8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size by Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer

List of Tables

Table 1: DSM-IV criteria for attention deficit hyperactivity disorder
Table 2: CD-10 criteria for hyperkinetic disorders
Table 3: ADHD Therapeutics, Marketed Products Overview, 2012
Table 4: ADHD Therapeutics, Pre-Clinical Pipeline, 2012
Table 5: ADHD Therapeutics, Phase I Pipeline, 2012
Table 6: ADHD Therapeutics, Phase II Pipeline, 2012
Table 7: ADHD Therapeutics, Phase III 2012
Table 8: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Table 9: M&A Deals by Deal Value

List of Figures

Figure 1: ADHD All Major Markets Market Size ($m) 2006-2011
Figure 2: ADHD All Major Markets Market Forecast ($m) 2012-2018
Figure 3: ADHD Annual Cost of Therapy All Markets ($) 2006-2018
Figure 4: ADHD Market Size US ($m) 2006-2011
Figure 5: ADHD Market Forecast US ($m) 2012-2018
Figure 6: ADHD Annual Cost of Therapy The US ($) 2006-2018
Figure 7: ADHD Market Size France ($m) 2006-2011
Figure 8: ADHD Market Forecast France ($m) 2012-2018
Figure 9: ADHD Annual Cost of Therapy France ($) 2006-2018
Figure 10: ADHD Market Size Germany ($m) 2006-2011
Figure 11: ADHD Market Forecast Germany ($m) 2012-2018
Figure 12: ADHD Annual Cost of Therapy Germany ($) 2006-2018
Figure 13: ADHD Market Size Italy ($m) 2006-2011
Figure 14: ADHD Market Forecast Italy ($m) 2012-2018
Figure 15: ADHD Annual Cost of Therapy Italy ($) 2006-2018
Figure 16: ADHD Market Size Spain ($m) 2006-2011
Figure 17: ADHD Market Forecast Spain ($m) 2012-2018
Figure 18: ADHD Annual Cost of Therapy Spain ($) 2006-2018
Figure 19: ADHD Market Size UK ($m) 2006-2011
Figure 20: ADHD Market Forecast UK ($m) 2012-2018
Figure 21: ADHD Annual Cost of Therapy The UK ($) 2006-2018
Figure 22: ADHD Market Size Japan ($m) 2006-2011
Figure 23: ADHD Market Forecast Japan ($m) 2012-2018
Figure 24: ADHD Therapeutics – Pipeline by Phase of Development, 2012
Figure 25: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Figure 26: ADHD Therapeutics – Pipeline by Program Type, 2012
Figure 27: ADHD Therapeutics – Inactive/Discontinued Pipeline Molecules by Target, 2012
Figure 28: Total Deals by Deal Type
Figure 29: Total Deals by Year
Figure 30: Total Deals by Geography
Figure 31: Total Deals by Deal Value
Figure 32: M&A Deals by Deal Type
Figure 33: M&A Deals by Year
Figure 34: M&A Deals by Geography
Figure 35: R&D Licensing Agreements Deals by Year
Figure 36: R&D Licensing Agreements Deals by Geography
Figure 37: R&D Licensing Agreements Deals by DealsValue
Figure 38: Co-Development Agreements Deals by Year
Figure 39: Co-Development Agreements Deals by Geography
Figure 40: Co-Development Agreements Deals by Deal Value
Figure 41: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Greece: asparagus market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the asparagus market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the asparagus market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

  • Protein Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    The pharmaceutical industry is witnessing a shift in focus from molecular drugs to protein based drugs due to its high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity. The market for protein drugs is segmented into antibody drugs, peptide hormones, blood products and enzymes market. The antibody segment is one of the fastest growing areas in this market. Some of the commercially available antibody drugs are Adcetris (brentuximab vedotin) marketed by Seattle Genetics and Millennium/Takeda and Kadcyla (trastuzumab emtansine) marketed by Genentech and...

  • Health Informatics Market - Global Industry Analysis, Market Share, Drivers, Restraints, Growth And Forecast, 2013 - 2019

    By - Transparency

    Health informatics is defined as the knowledge, skills, and tools that enable the information to be collected, managed, used and shared for supporting the delivery of healthcare services and promoting health. Health informatics is one of the fastest growing segments of information technology and computer science. It is an application of information technology and computing disciplines for solving the problems in the field of healthcare. The need to reduce cost and increase efficiency within healthcare sectors is leading to the development of new healthcare concepts like managed care....